- Home
- BLRX vs FEMY Comparison
BLRX vs FEMY Comparison
Compare BLRX & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- FEMY
- Stock Information
- Founded
- BLRX 2003
- FEMY 2004
- Country
- BLRX Israel
- FEMY United States
- Employees
- BLRX N/A
- FEMY N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- FEMY Medical/Dental Instruments
- Sector
- BLRX Health Care
- FEMY Health Care
- Exchange
- BLRX Nasdaq
- FEMY Nasdaq
- Market Cap
- BLRX 17.0M
- FEMY 18.6M
- IPO Year
- BLRX 2011
- FEMY 2021
- Fundamental
- Price
- BLRX $3.67
- FEMY $0.38
- Analyst Decision
- BLRX Strong Buy
- FEMY Strong Buy
- Analyst Count
- BLRX 2
- FEMY 3
- Target Price
- BLRX $19.00
- FEMY $7.33
- AVG Volume (30 Days)
- BLRX 32.7K
- FEMY 1.6M
- Earning Date
- BLRX 08-14-2025
- FEMY 08-08-2025
- Dividend Yield
- BLRX N/A
- FEMY N/A
- EPS Growth
- BLRX N/A
- FEMY N/A
- EPS
- BLRX N/A
- FEMY N/A
- Revenue
- BLRX $17,251,000.00
- FEMY $1,887,016.00
- Revenue This Year
- BLRX N/A
- FEMY $103.55
- Revenue Next Year
- BLRX N/A
- FEMY $148.13
- P/E Ratio
- BLRX N/A
- FEMY N/A
- Revenue Growth
- BLRX 1.19
- FEMY 98.61
- 52 Week Low
- BLRX $2.30
- FEMY $0.31
- 52 Week High
- BLRX $26.80
- FEMY $1.80
- Technical
- Relative Strength Index (RSI)
- BLRX 44.89
- FEMY 24.33
- Support Level
- BLRX $3.42
- FEMY $0.36
- Resistance Level
- BLRX $3.79
- FEMY $0.42
- Average True Range (ATR)
- BLRX 0.25
- FEMY 0.06
- MACD
- BLRX 0.02
- FEMY -0.01
- Stochastic Oscillator
- BLRX 47.17
- FEMY 16.48
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.